Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study

Heinz Ludwig, Matti Aapro, Carsten Bokemeyer, Karen MacDonald, Pierre Soubeyran, Matthew Turner, Tara Albrecht, Ivo L Abraham

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objectives: To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe. Methods: Retrospective pharmacoepidemiologic study of 2192 patients from 307 centres. Minimum of 3 visits over 8-10 weeks with ESA treatment initiated at visit 1. Results: Most patients were treated per guidelines, except for low iron supplementation rates. Mean Hb rose from 9.54 ± 0.95 g/dl to 10.88 ± 1.49 g/dl at visit 3, without concomitant rise in WHO/ECOG score. Response rates were 65.0% (Hb increase ↑ ≥ 1 g/dl); 54.3% (Hb increase ↑ ≥ 1 g/dl in 8 weeks); 38.9% (haematopoietic response); 33.7% (Hb increase ↑ ≥ 2 g/dl) and 18.8% (Hb between12.0 and 12.9 g/dl). Conclusions: Treatment patterns were guideline congruent, except for (intravenous) iron supplementation. Hb increased by 1.34 g/dl. A net erythropoiesis boost of Hb ≥ 1 g/dl is attainable in two-thirds of patients and should be condensed to 8 weeks on an individual patient basis. Anaemia management in Europe has improved significantly. The general effectiveness and relative safety of judicious ESA treatment are evident.

Original languageEnglish (US)
Pages (from-to)1603-1615
Number of pages13
JournalEuropean Journal of Cancer
Volume45
Issue number9
DOIs
StatePublished - Jun 2009

Fingerprint

Anemia
Hematinics
Neoplasms
Iron
Guidelines
Therapeutics
Erythropoiesis
Retrospective Studies
Safety

Keywords

  • Anaemia
  • Cancer
  • Erythropoietin
  • Europe
  • Haemoglobin
  • Outcomes
  • Response
  • Treatment patterns

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe : Findings from the Anaemia Cancer Treatment (ACT) study. / Ludwig, Heinz; Aapro, Matti; Bokemeyer, Carsten; MacDonald, Karen; Soubeyran, Pierre; Turner, Matthew; Albrecht, Tara; Abraham, Ivo L.

In: European Journal of Cancer, Vol. 45, No. 9, 06.2009, p. 1603-1615.

Research output: Contribution to journalArticle

Ludwig, Heinz ; Aapro, Matti ; Bokemeyer, Carsten ; MacDonald, Karen ; Soubeyran, Pierre ; Turner, Matthew ; Albrecht, Tara ; Abraham, Ivo L. / Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe : Findings from the Anaemia Cancer Treatment (ACT) study. In: European Journal of Cancer. 2009 ; Vol. 45, No. 9. pp. 1603-1615.
@article{dbbb329bb6a34ba7bbb14fd62e5b9236,
title = "Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study",
abstract = "Objectives: To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe. Methods: Retrospective pharmacoepidemiologic study of 2192 patients from 307 centres. Minimum of 3 visits over 8-10 weeks with ESA treatment initiated at visit 1. Results: Most patients were treated per guidelines, except for low iron supplementation rates. Mean Hb rose from 9.54 ± 0.95 g/dl to 10.88 ± 1.49 g/dl at visit 3, without concomitant rise in WHO/ECOG score. Response rates were 65.0{\%} (Hb increase ↑ ≥ 1 g/dl); 54.3{\%} (Hb increase ↑ ≥ 1 g/dl in 8 weeks); 38.9{\%} (haematopoietic response); 33.7{\%} (Hb increase ↑ ≥ 2 g/dl) and 18.8{\%} (Hb between12.0 and 12.9 g/dl). Conclusions: Treatment patterns were guideline congruent, except for (intravenous) iron supplementation. Hb increased by 1.34 g/dl. A net erythropoiesis boost of Hb ≥ 1 g/dl is attainable in two-thirds of patients and should be condensed to 8 weeks on an individual patient basis. Anaemia management in Europe has improved significantly. The general effectiveness and relative safety of judicious ESA treatment are evident.",
keywords = "Anaemia, Cancer, Erythropoietin, Europe, Haemoglobin, Outcomes, Response, Treatment patterns",
author = "Heinz Ludwig and Matti Aapro and Carsten Bokemeyer and Karen MacDonald and Pierre Soubeyran and Matthew Turner and Tara Albrecht and Abraham, {Ivo L}",
year = "2009",
month = "6",
doi = "10.1016/j.ejca.2009.02.003",
language = "English (US)",
volume = "45",
pages = "1603--1615",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe

T2 - Findings from the Anaemia Cancer Treatment (ACT) study

AU - Ludwig, Heinz

AU - Aapro, Matti

AU - Bokemeyer, Carsten

AU - MacDonald, Karen

AU - Soubeyran, Pierre

AU - Turner, Matthew

AU - Albrecht, Tara

AU - Abraham, Ivo L

PY - 2009/6

Y1 - 2009/6

N2 - Objectives: To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe. Methods: Retrospective pharmacoepidemiologic study of 2192 patients from 307 centres. Minimum of 3 visits over 8-10 weeks with ESA treatment initiated at visit 1. Results: Most patients were treated per guidelines, except for low iron supplementation rates. Mean Hb rose from 9.54 ± 0.95 g/dl to 10.88 ± 1.49 g/dl at visit 3, without concomitant rise in WHO/ECOG score. Response rates were 65.0% (Hb increase ↑ ≥ 1 g/dl); 54.3% (Hb increase ↑ ≥ 1 g/dl in 8 weeks); 38.9% (haematopoietic response); 33.7% (Hb increase ↑ ≥ 2 g/dl) and 18.8% (Hb between12.0 and 12.9 g/dl). Conclusions: Treatment patterns were guideline congruent, except for (intravenous) iron supplementation. Hb increased by 1.34 g/dl. A net erythropoiesis boost of Hb ≥ 1 g/dl is attainable in two-thirds of patients and should be condensed to 8 weeks on an individual patient basis. Anaemia management in Europe has improved significantly. The general effectiveness and relative safety of judicious ESA treatment are evident.

AB - Objectives: To examine anaemia management in cancer patients treated with erythropoiesis-stimulating agents (ESAs) in Europe. Methods: Retrospective pharmacoepidemiologic study of 2192 patients from 307 centres. Minimum of 3 visits over 8-10 weeks with ESA treatment initiated at visit 1. Results: Most patients were treated per guidelines, except for low iron supplementation rates. Mean Hb rose from 9.54 ± 0.95 g/dl to 10.88 ± 1.49 g/dl at visit 3, without concomitant rise in WHO/ECOG score. Response rates were 65.0% (Hb increase ↑ ≥ 1 g/dl); 54.3% (Hb increase ↑ ≥ 1 g/dl in 8 weeks); 38.9% (haematopoietic response); 33.7% (Hb increase ↑ ≥ 2 g/dl) and 18.8% (Hb between12.0 and 12.9 g/dl). Conclusions: Treatment patterns were guideline congruent, except for (intravenous) iron supplementation. Hb increased by 1.34 g/dl. A net erythropoiesis boost of Hb ≥ 1 g/dl is attainable in two-thirds of patients and should be condensed to 8 weeks on an individual patient basis. Anaemia management in Europe has improved significantly. The general effectiveness and relative safety of judicious ESA treatment are evident.

KW - Anaemia

KW - Cancer

KW - Erythropoietin

KW - Europe

KW - Haemoglobin

KW - Outcomes

KW - Response

KW - Treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=66149150959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149150959&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.02.003

DO - 10.1016/j.ejca.2009.02.003

M3 - Article

C2 - 19278851

AN - SCOPUS:66149150959

VL - 45

SP - 1603

EP - 1615

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -